Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression

NCT03482882 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT03482882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03482882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2018
Completion date
July 24, 2019
Enrollment
47 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

treatment of depression in adults with parkinson's disease (pd)